Blog
RSS FeedPosted by Michael Wonder on 09 Aug 2024
BioMarin announces updated strategy for Roctavian to focus on US, Germany and Italy
5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025. ...
Posted by Michael Wonder on 19 Jul 2022
German Government announces bill to drastically slash drug reimbursement
19 July 2022 - On 8 July 2022, the German Health Ministry has officially shared the second edition of a new ...
Posted by Michael Wonder on 04 Apr 2022
Bluebird Bio has serious cash flow concerns; inability to strike reimbursement deals in Europe partly to blame
3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic ...
Posted by Michael Wonder on 20 Aug 2015
Afatinib: added benefit in certain mutations confirmed by IQWiG
17 August 2015 - Afatinib dimaleate (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients ...